SEARCH

SEARCH BY CITATION

References

  • 1
    Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 5261.
  • 2
    Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 736.
  • 3
    Naoumov NV, Scheinder R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 53843.
  • 4
    Brunetto MR, Olivieri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen. Hepatology 1989; 10: 198202.
  • 5
    Carman WF, Jacyna MR, Hadziyannis S, et al. Mutations preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 58891.
  • 6
    Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 407781.
  • 7
    Dienstag J, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 165761.
  • 8
    Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 618.
  • 9
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 30: 10827.
  • 10
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 3006.
  • 11
    Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B. J Hepatol 1999; 30 (Suppl. 1): 117.
  • 12
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 13
    Buti M, Cortina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 2705.
  • 14
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 15
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 7147.
  • 16
    Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 16707.
  • 17
    Lai C-L, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 68796.
  • 18
    Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998; 29: 15168.
  • 19
    Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 114553.
  • 20
    Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 11639.
  • 21
    Jardi R, Rodriguez F, Buti M, et al. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat 2001; 8: 46571.
  • 22
    Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 16417.
  • 23
    Stuyver L, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 7517.
  • 24
    Zoulim F, Trepo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 2000; 32: 11723.
  • 25
    Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5 years of lamivudine therapy. J Hepatol 2003; 37: 82430.
  • 26
    Cianco A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine. Hepatology 2004; 39: 6473.
  • 27
    Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during antiviral therapy: evaluation and performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2000; 40: 372934.
  • 28
    Jardi R, Rodríguez-Frias F, Buti M, et al. Mutations in the basic core promoter region of hepatitis B. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol 2004; 40: 50714.
  • 29
    Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 2735.
  • 30
    Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 7027.
  • 31
    Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 13935.
  • 32
    Si Ahmed SN, Tavan D, Pichoud C, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations under in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 107888.
  • 33
    Melegari N, Scaglioni P, Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1999; 27: 62833.
  • 34
    Fu L, Cheng Y-C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(−)SddC (3TC) resistance. Biochem Pharmacol 1998; 55: 156772.
  • 35
    Grandjacques C, Pradat P, Stuyver M, et al. Rapid detection of genotypes and precore mutations in the precore promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 4309.